Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 37 articles:
HTML format
Text format



Single Articles


    May 2018
  1. YARMOLINSKY J, Bonilla C, Haycock PC, Langdon RJQ, et al
    Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis.
    J Natl Cancer Inst. 2018 May 17. pii: 4996958. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  2. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    March 2018
  3. WALLERSTEDT A, Strom P, Gronberg H, Nordstrom T, et al
    Risk of Prostate Cancer in Men Treated With 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Natl Cancer Inst. 2018 Mar 14. pii: 4935092. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. THOMPSON I JR., Goodman P, Tangen C
    Reduced Risk of Prostate Cancer With 5alpha-Reductase Inhibitors.
    J Natl Cancer Inst. 2018 Mar 14. pii: 4935098. doi: 10.1093.
    PubMed     Text format    


  5. UNGER JM, Hershman DL, Till C, Tangen CM, et al
    Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst. 2018 Mar 9. pii: 4925555. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  6. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  7. WYATT AW, Annala M, Aggarwal R, Beja K, et al
    Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  8. BROUGHMAN JR, Basak R, Nielsen ME, Reeve BB, et al
    Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.
    J Natl Cancer Inst. 2017 Oct 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  9. CONTI DV, Wang K, Sheng X, Bensen JT, et al
    Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    June 2017
  10. LESTER-COLL NH, Johnson S, Magnuson WJ, Goldhaber SZ, et al
    Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


    April 2017
  11. BRIOLLAIS L, Ozcelik H, Xu J, Kwiatkowski M, et al
    Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    March 2017
  12. KELLY SP, Graubard BI, Andreotti G, Younes N, et al
    Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  13. KELLY SP, Graubard BI, Andreotti G, Younes N, et al
    Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2017;109:1-9.
    PubMed     Text format     Abstract available


    February 2017
  14. POLLACK A, Kwon D, Walker G, Khor LY, et al
    Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
    J Natl Cancer Inst. 2017;109:1-8.
    PubMed     Text format     Abstract available


    January 2017

  15. Stat Bite Prostate Cancer Incidence and Death Rates.
    J Natl Cancer Inst. 2017;109:6.
    PubMed     Text format    


  16. SCHMIDT C
    Reconsidering Prostate Cancer Screening.
    J Natl Cancer Inst. 2017;109:1-2.
    PubMed     Text format    


  17. GAO X, Li LY, Rassler J, Pang J, et al
    Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    December 2016
  18. UNGER JM, Till C, Thompson IM Jr, Tangen CM, et al
    Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    November 2016
  19. YANG M, Sesso HD, Colditz GA, Ma J, et al
    Effect Modification by Time Since Blood Draw on the Association Between Circulating Fatty Acids and Prostate Cancer Risk.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  20. ALLEN NE, Travis RC, Appleby PN, Albanes D, et al
    Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    October 2016
  21. BRATT O, Drevin L, Akre O, Garmo H, et al
    Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    September 2016
  22. SIDDIQUI MM, George AK, Rubin R, Rais-Bahrami S, et al
    Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    July 2016
  23. HAN Y, Rand KA, Hazelett DJ, Ingles SA, et al
    Prostate Cancer Susceptibility in Men of African Ancestry at 8q24.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  24. SHIOTA M, Fujimoto N, Imada K, Yokomizo A, et al
    Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


    May 2016
  25. ASIM M, Massie CE, Orafidiya F, Pertega-Gomes N, et al
    Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  26. ABOU DS, Ulmert D, Doucet M, Hobbs RF, et al
    Whole-Body and Microenvironmental Localization of Radium-223 in Naive and Mouse Models of Prostate Cancer Metastasis.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  27. ZHENG Z, Yabroff KR, Guy GP Jr, Han X, et al
    Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  28. DELUDE C
    Prostate Cancer: A New Twist on Active Surveillance.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    April 2016

  29. Stat Bite Percentage of New Cases by Age Group For Prostate Cancer (2008-2012).
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  30. SCHMIDT C
    Active Surveillance Gets Personal.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    March 2016
  31. KENFIELD SA, Batista JL, Jahn JL, Downer MK, et al
    Development and Application of a Lifestyle Score for Prevention of Lethal Prostate Cancer.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    February 2016
  32. AHEARN TU, Pettersson A, Ebot EM, Gerke T, et al
    A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  33. MEEKS HD, Song H, Michailidou K, Bolla MK, et al
    BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  34. KIM JJ, Tosteson AN, Zauber AG, Sprague BL, et al
    Cancer Models and Real-world Data: Better Together.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


  35. TENG CJ, Hu YW, Chen SC, Yeh CM, et al
    Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    January 2016
  36. ALFANO CM, Bluethmann SM, Tesauro G, Perna F, et al
    NCI Funding Trends and Priorities in Physical Activity and Energy Balance Research Among Cancer Survivors.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    December 2015
  37. SWEENEY C, Nakabayashi M, Regan M, Xie W, et al
    The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
    J Natl Cancer Inst. 2015;107:djv261.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: